GEVELOT S.A.

  • ISIN: FR0000033888
  • Land: France

Nachricht vom 11.06.2020 | 18:00

GEVELOT S.A.: AGM 2020 Press release

GEVELOT S.A.
GEVELOT S.A.: AGM 2020 Press release

11-Jun-2020 / 18:00 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


 

 

 

GEVELOT S.A.

Limited company capitalised at 26,932,500 euros

Head office: 6, boulevard Bineau 92300 Levallois-Perret, France

562 088 542 R.C.S. NANTERRE

 

 

 

PRESS RELEASE - 11 JUNE 2020

 

 

The Annual General Meeting held on 11 June 2020 approved the Company's financial statements and consolidated financial statements for the year 2019.

 

All the resolutions proposed by the Board of Directors have been adopted.

 

The consolidated revenue for the 2019 financial year, consisting mainly of the Pumps Sector, the other sector relating to the real estate activity of the Holding Company, amounted to € 103.7 million compared to € 94.2 million in 2018, up 10.1%. At constant scope and exchange rates, the increase was 6.8%.

 

The net income accruing to Gévelot, the consolidating company, for the financial year 2019 amounted to € 8.6 million in profit against a profit of € 6.0 million in 2018.

 

The Gévelot parent company generated a net profit of € 3.1 million compared to € 3.2 million, also a beneficiary in 2018.

 

It has been decided to pay a dividend set at € 1.60 per share as of June 19, 2020, compared to € 1.80 last year.

 

Significant negative impacts are expected for the year 2020 from the Covid-19 health crisis, both on the commercial activity and profitability of our Group.

 

Our ability to adapt and the efforts made by all of our employees in this difficult context should nonetheless allow our Group to face the expected difficulties.

 

 

Website Gévelot, Euronext Growth, Amf (Onde)

 


Regulatory filing PDF file

File: Gevelot AGM 2020 Press release

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021